Form 4: Revance Therapeutics Chief Commercial Officer Disposes of Shares Following Merger

Erica Jordan, Chief Commercial Officer of Revance Therapeutics, disposes of shares and restricted stock units following the completion of a merger with Crown Laboratories.

Summary

• Erica Jordan, Chief Commercial Officer of Revance Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 4, 2025, Jordan disposed of 6,922 shares of common stock at a price of $3.65 per share, totaling $25,265.30.
• The disposal was pursuant to the merger agreement with Crown Laboratories, Inc.
• On February 6, 2025, Jordan disposed of 107,942 shares of common stock.
• Unvested restricted stock units (RSUs) held by Jordan were canceled and converted into the right to receive cash based on the merger price of $3.65 per share.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to a merger. It doesn't convey strong positive or negative sentiment, but rather reports factual transactions.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects the completion of a merger transaction, which is a common occurrence in the biotechnology and pharmaceutical industries as companies seek to consolidate resources, expand product portfolios, or gain access to new technologies.

Stakeholder Impact

• Shareholders who tendered their shares received $3.65 per share.
• Employees with unvested RSUs received a cash payment equivalent to the value of their RSUs at the merger price.

Key Dates

Keywords

Form 4, Revance Therapeutics, Crown Laboratories, Merger, Share Disposal, Erica Jordan, Chief Commercial Officer, RVNC, Beneficial Ownership